Navigation Links
New hope for hepatitis C sufferers

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.

The scientists, who are also attached to the Institute of Medical and Veterinary Science and Royal Adelaide Hospital, hope to identify antiviral proteins that can be used in the fight against hepatitis C.

Currently there is no effective vaccine and the existing treatment is expensive and often causes severe side effects. The success rate also varies between 50-80% so many sufferers cannot be helped by current approaches.

The funds, awarded by the National Health and Medical Research Council (NHMRC), are part of a larger $17.7 million joint program grant, tackling both HIV/AIDS and hepatitis C and involving nine scientists from across Australia.

Dr Beard said this was the first Australian program grant awarded to study both HIV/AIDS and HCV/hepatitis C.

The development of vaccines and better treatments for both these viruses are urgent global health priorities, Dr Beard said. This program brings together a team of researchers with skills in basic virology and immunology with experts who can translate laboratory findings into human clinical trials.

This latest grant is an adjunct to three NHMRC project grants awarded to Dr Beards team in the past two years specifically for hepatitis C research.

In 2006 the virologist was awarded more than $894,000 to investigate the link between alcohol and hepatitis C, and the basic mechanisms of liver disease.

In Australia, more than 264,000 people have been infected with the hepatitis C virus and there are approximately 10,000 new infections per year. A proportion of these are intravenous drug users, with alcohol playing a significant role in disease progression, Dr Beard said.

He said vaccines had been trialled for HIV, but with little success. There is antiretroviral treatment but this does not eradicate HIV, it only keeps it under control for a period of time. It is also very expensive and therefore not accessible on a global scale.

Dr Beard said the program would provide a pipeline to develop and test vaccines and novel treatments in a timely fashion.


Contact: Michael Beard
University of Adelaide

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Who will recover spontaneously from hepatitis C virus infection
3. Possible hepatitis C vaccine
4. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
5. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
6. New Swedish research hope for millions of sufferers
Post Your Comments:
Related Image:
New hope for hepatitis C sufferers
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... of a new closed system for isolating adipose-derived stem cells. The announcement starts a ... of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction of ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening ... the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s ... most advanced protocols and techniques in stem cell medicine to patients from around the world. ...
(Date:11/30/2015)... (NYSE: BIOA ), a leader in renewable materials, today ... Climate Pledge, alongside more than 140 companies from across the ... demonstrate an ongoing commitment to climate action and to voice ... Paris climate negotiations. Sarnia, Canada ... --> BioAmber uses biotechnology to convert renewable sugars ...
Breaking Biology Technology: